Specifications
- Assay duration:Multiple steps
- Assay Type (ELISA with LOV):Sandwich
- Conjugate ELISA:Biotin
- Format:Pre-coated
- Host:Rabbit
- Primary antibody reactivity:Dog
- Target protein:MCP1
- Size:1 Kit
- Sample Type:Serum, Plasma, Tissue homogenates, Cell lysates, Cell culture supernates and other biological fluids
- Cross Reactivity:No significant cross-reactivity or interference between Monocyte Chemotactic Protein 1 (MCP1) and analogues was observed
- Detection Method:Colorimetric
- Time to Results:3 h
- Shelf Life:12 Months
- Detection Range:3.12 - 200 pg/ml
- Storage Temperature:4 °C for one month (frequent use), −20 °C for one year
- Sample Volume:100 µl
- Sensitivity:1.17 pg/ml
- Regulatory Status:RUO
- Cat. No.:MSPP-SEA087CA
- No. of tests:96 wells
Specifications
About this item
This assay has high sensitivity and excellent specificity for detecting Dog MCP1 (Monocyte Chemotactic Protein 1). The assay range is from 3.12 to 200 pg/ml (Sandwich kit) with a sensitivity of 1.17 pg/ml. There is no detectable cross-reactivity with other relevant proteins. Activity loss rate and accelerated stability test ect have been conducted to guarantee the best performance of the products after long storage and delivery.
- High sensitivity and specificity
- Perfect reproducibility and consistency across batches
- Quality control with three-level inspections
- Wide range of targets/species available
- Intra-Assay: CV <10%, Inter-Assay: CV <12%
CCL2 is a small cytokine belonging to the CC chemokine family that is also known as monocyte chemotactic protein-1 (MCP-1). This chemokine is produced predominantly by macrophages and endothelial cells and is a potent chemotactic factor for monocytes as a protein precursor containing signal peptide of 23 amino acids and a mature peptide of 76 amino acids. It is a monomeric polypeptide, with a molecular weight of approximately 13 kDa. CCL2 recruits monocytes, memory T cells, and dendritic cells to sites of tissue injury and infection. Expression of this proinflammatory chemokine is increased in atherosclerotic lesions, and inhibition of its expression or that of its receptor, CC chemokine receptor 2 (CCR2), reduces the extent of atheroma formation in hypercholesterolemic mice.